高级搜索
李笑宇, 张楠, 狄文. 卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进[J]. 肿瘤防治研究, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677
引用本文: 李笑宇, 张楠, 狄文. 卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进[J]. 肿瘤防治研究, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677
LI Xiaoyu, ZHANG Nan, DI Wen. Platinum Resistance in Ovarian Cancer: Limitations of PFI Binary Classification and Potential Improvements[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677
Citation: LI Xiaoyu, ZHANG Nan, DI Wen. Platinum Resistance in Ovarian Cancer: Limitations of PFI Binary Classification and Potential Improvements[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 813-819. DOI: 10.3971/j.issn.1000-8578.2024.24.0677

卵巢癌铂耐药:PFI“二分法”的局限性与可能的改进

Platinum Resistance in Ovarian Cancer: Limitations of PFI Binary Classification and Potential Improvements

  • 摘要: 卵巢癌是一种较为常见的妇科恶性肿瘤,临床上主要通过无铂间期将复发性卵巢癌分为铂耐药性与铂敏感性,分别对应不同的治疗方式及预后。铂耐药性卵巢癌的治疗十分困难,随着研究的深入,有学者提出根据无铂间期的“二分法”存在一定局限性。因此,本文将对复发性卵巢癌的分类、铂耐药性卵巢癌的治疗困境、无铂间期“二分法”的局限性与新的分类思路作一综述,帮助临床工作者更好地了解卵巢癌分类方面的研究进展,从而制定更加有效的治疗策略。

     

    Abstract: Ovarian cancer is a common gynecologic malignancy. In clinical practice, recurrent ovarian cancer is mainly classified into two categories on the basis of platinum-free interval, platinum-resistant and platinum-sensitive, corresponding to different treatment modalities and prognoses. The treatment of platinum-resistant ovarian cancer is challenging. Some scholars have pointed out limitations in the binary classification of platinum-free interval. In this article, the classification of recurrent ovarian cancer, the treatment challenges of platinum-resistant ovarian cancer, the limitations of the platinum-free interval binary classification, and new classification perspectives were reviewed to help physicians enhance their understanding on the research progress in ovarian cancer classification and develop more effective treatment strategies.

     

/

返回文章
返回